drugset / Trial / NCT00004216

VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy

NCT00004216

Phase 1 Completed Vion Pharmaceuticals
Treatment

Summary

RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of VNP20009 in treating patients who have advanced or metastatic solid tumors that have not responded to previous therapy.

Timeline

Start
1999-08
Primary completion
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject VNP20009 Other / unclassified Other
Background Cefixime Other / unclassified Oral
Background Ceftriaxone Other / unclassified Intravenous
Background Ciprofloxacin Small molecule Intravenous
Background trimethoprim-sulfamethoxazole Unknown Oral